Multifaceted Functions of STING in Human Health and Disease: from Molecular Mechanism to Targeted Strategy
Overview
Pharmacology
Affiliations
Since the discovery of Stimulator of Interferon Genes (STING) as an important pivot for cytosolic DNA sensation and interferon (IFN) induction, intensive efforts have been endeavored to clarify the molecular mechanism of its activation, its physiological function as a ubiquitously expressed protein, and to explore its potential as a therapeutic target in a wide range of immune-related diseases. With its orthodox ligand 2'3'-cyclic GMP-AMP (2'3'-cGAMP) and the upstream sensor 2'3'-cGAMP synthase (cGAS) to be found, STING acquires its central functionality in the best-studied signaling cascade, namely the cGAS-STING-IFN pathway. However, recently updated research through structural research, genetic screening, and biochemical assay greatly extends the current knowledge of STING biology. A second ligand pocket was recently discovered in the transmembrane domain for a synthetic agonist. On its downstream outputs, accumulating studies sketch primordial and multifaceted roles of STING beyond its cytokine-inducing function, such as autophagy, cell death, metabolic modulation, endoplasmic reticulum (ER) stress, and RNA virus restriction. Furthermore, with the expansion of the STING interactome, the details of STING trafficking also get clearer. After retrospecting the brief history of viral interference and the milestone events since the discovery of STING, we present a vivid panorama of STING biology taking into account the details of the biochemical assay and structural information, especially its versatile outputs and functions beyond IFN induction. We also summarize the roles of STING in the pathogenesis of various diseases and highlight the development of small-molecular compounds targeting STING for disease treatment in combination with the latest research. Finally, we discuss the open questions imperative to answer.
Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy.
Zhang J, Wang F, Sun Z, Ye J, Chu H J Nanobiotechnology. 2025; 23(1):161.
PMID: 40033359 PMC: 11874808. DOI: 10.1186/s12951-025-03236-x.
Zhuo S, Chen X, Zhao L, Wang T, Su J, Yang T RSC Med Chem. 2025; .
PMID: 40008189 PMC: 11848399. DOI: 10.1039/d4md00475b.
Profile of STING agonist and inhibitor research: a bibliometric analysis.
Wang X, Wang Q, Gao Y, Jiang L, Tang L Front Pharmacol. 2025; 16:1528459.
PMID: 40008133 PMC: 11850258. DOI: 10.3389/fphar.2025.1528459.
Jin Y, Fleishman J, Ma Y, Jing X, Guo Q, Shang W Drug Des Devel Ther. 2025; 19:1025-1041.
PMID: 39967903 PMC: 11834678. DOI: 10.2147/DDDT.S506537.
cGAS-STING targeting offers therapy choice in lung diseases.
Wang Y, Zhang X, Wang W, Zhang Y, Fleishman J, Wang H Biol Direct. 2025; 20(1):20.
PMID: 39920718 PMC: 11806777. DOI: 10.1186/s13062-025-00611-4.